Post-Transplantation Proteinuria and Sirolimus
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
To the Editor: Proteinuria may develop in renal-transplant recipients who have converted from treatment with calcineurin inhibitors to treatment with sirolimus1; the mechanism of this occurrence is unknown. We hypothesized that the antiangiogenic properties of sirolimus might be responsible. We determined the plasma concentrations and renal expression of vascular endothelial growth factor (VEGF) in a specimen from a renal-allograft biopsy performed to evaluate post-transplantation proteinuria during sirolimus conversion in a patient with Kaposi's syndrome. A 68-year-old man with alcoholic cirrhosis and end-stage renal disease due to IgA nephropathy underwent cadaveric liver and renal transplantation in May 1996. Eight years . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Cited by
The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response
Weichhart, T., Costantino, G., Poglitsch, M., Rosner, M., Zeyda, M., Stuhlmeier, K. M., Kolbe, T., Stulnig, T. M., Hörl, W. H., Hengstschläger, M., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.012 · Cited by 801
Schena, F. P., Pascoe, M. D., Alberu, J., del Carmen Rial, M., Oberbauer, R., Brennan, D. C., Campistol, J. M., Racusen, L., Polinsky, M. S., Goldberg-Alberts, R., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181927a41 · Cited by 583
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
Mirza, A. Z., Althagafi, I. I., & Shamshad, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.067 · Cited by 544
FLIP-mediated autophagy regulation in cell death control
Lee, J.-S., Li, Q., Lee, J.-Y., Lee, S.-H., Jeong, J. H., Lee, H.-R., Chang, H., Zhou, F.-C., Gao, S.-J., Liang, C., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1980 · Cited by 406
“Consequently, FLIP expression effectively represses cell death with autophagy, as induced by rapamycin, an mTor inhibitor and an effective anti-tumour drug against KSHV-induced Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL”
Metadata
- Authors
- Izzedine, H., Brocheriou, I., & Frances, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-10
- Volume
- 353
- Issue
- 19
- Pages
- 2088-2089
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2066573789
- Cited by
- 110
- References
- 1
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Post-Transplantation Proteinuria and Sirolimus. https://app.cochat.ai/papers/10.1056/nejm200511103531922
- The paper
- Izzedine, H., Brocheriou, I., & Frances, C. (2005). Post-Transplantation Proteinuria and Sirolimus. New England Journal of Medicine. https://doi.org/10.1056/nejm200511103531922
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.